Antibe Therapeutics Inc(Pre-Merger) ATBPF

TSX promo video ...

[MrMugsy]

Did anyone catch what Dan said about "Fully validating the $30B opportunity" if we solve the problem.

Was he talking specifically about the first drug ?

If so, then he's already communicating the OA, RA and other indications.

-----

https://www.newswire.ca/news-releases/tmx-group-antibe-therapeutics-c-suite-at-the-open-880785937.html

[Harper75]

If I'm following correctly, (the quality is a tad poor) Dan is talking about the first drug still at 2:05 and then mentions the second drug in the pipeline at 2:30. Good catch...I think

[MrMugsy]

And Dan recently said that OA is worth $16B and all other indications is worth the same - so another $16B roughly. He also said they would move quickly into those other indications. All three drugs take us to $50B+ Then you take is last quote and it looks really exciting ... “We’re going to initiate a whole new field around what are called the gaseous mediators: nitric oxide, hydrogen sulfide,

[Inthepez]

Deans on mugsy. I see no reason why you can’t factor in Rheumatoid arthritis as well. Both present the same clinically and first line of treat are also the same. The difference is found out once you start doing blood tests that show signs of autoimmune markers, so they might through immunosuppressant with NSAIDs for RA. The buyers know this info and have their clinicians turned advisors who

[HarveyTwoface]

Global NSAID market 2020 is about $16B, not only for OA. https://www.marketwatch.com/press-release/non-steroidal-anti-inflammatory-drugs-market-size-growth-2020-covid-19-impact-on-healthcare-sector-share-business-regional-analysis-competitive-landscape-with-global-forecast-to-2027-2020-11-05?tesla=y